Trial Profile
CIRG (TRIO) 011/NSABP B-44-I / B020906: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Trastuzumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
- Indications Adenocarcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms BETH
- Sponsors Roche
- 19 Jan 2022 This trial has been completed in Slovakia, according to European Clinical Trials Database record.
- 16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.
- 05 Oct 2021 This trial has been completed in Spain (End Date: 17 Apr 2014), according to European Clinical Trials Database record.